 |
| Proton Pump Inhibitors Market |
The global Proton Pump Inhibitors Market is estimated to be valued at US$ 3.29 Bn in 2023 and is expected to exhibit a CAGR of 4.3% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Proton pump inhibitors are a type of medication which reduce the amount of acid
produced in the stomach. They are commonly used for conditions like acid
reflux, ulcers and heartburn. Proton pump inhibitors work by blocking the
action of acid-producing cells in the stomach lining. This allows ulcers to
heal and reduces the symptoms of acid reflux.
Market key trends:
The rise in prevalence of acid reflux and ulcers has been a major driver of
growth for the proton pump inhibitors market. According to studies, over 15
million Americans experience acid reflux on a weekly basis. Increase in obesity
and poor lifestyle habits have contributed to the increasing incidence of acid
reflux. Additionally, increasingly sedentary lifestyle and consumption of
fatty, spicy foods trigger acid reflux symptoms in many individuals. New
product launches by key players with formulations enabling once-a-day dosing
have further boosted the adoption of proton pump inhibitors for management of
acid reflux and ulcers..
Segment Analysis
The global proton pump inhibitors market is dominated by the omeprazole
sub-segment owing to its significant popularity as an effective treatment
option for acid reflux and heartburn. Some key advantages of omeprazole over
other PPIs include better tolerability, efficacy, being less expensive, and
availability of cheaper generic versions.
Key Takeaways
The global Proton
Pump Inhibitors Market is
expected to witness high growth, exhibiting CAGR of 4.3% over the forecast period, due to increasing prevalence
of acid reflux diseases.
Regional analysis
North America currently dominates the global proton pump inhibitors market due
to high awareness levels about acid reflux diseases and rising obese
population. Europe is also a major market exhibiting significant growth.
Key players
Key players operating in the proton pump inhibitors market are AstraZeneca
PLC/AB, Bayer AG, Pfizer Inc., Cadila Pharmaceuticals Limited, Eisai Pharmaceuticals
India Pvt. Ltd, Santarus, Inc., Wyeth, LLC, Janssen Pharmaceutica, Takeda
Pharmaceutical Company Limited, Sanofi S.A, Aurobindo Pharma, Perrigo Company
plc, Dr. Reddy's Laboratories, Aralez Pharmaceuticals Inc., RedHill Biopharma
Ltd (ADR) and Cipla Limited.
Read More,
https://www.insightprobing.com/proton-pump-inhibitors-market-trends-size-and-share-analysis/
0 Comments